1. Evolving Paradigms in the Management of HR-Positive Breast Cancer

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. CDK4/6 Inhibitors

6. PALOMA-1: First-Line Therapy With Palbociclib

7. PALOMA-1: Grade 3/4 Adverse Effects

8. PALOMA-2: First-Line Therapy With Palbociclib

9. MONALEESA-2: First-Line Therapy With Ribociclib

10. PFS in PALOMA-2 and MONALEESA-2

11. MONALEESA-2: Grade 3/4 Adverse Events

12. Abemaciclib

13. PALOMA-3: Palbociclib in Progressive Disease

14. MONARCH 2: Abemaciclib in Progressive Disease

15. CDK4/6 Inhibitors as Single-Agent Therapy

16. Survival

17. Fulvestrant

18. FALCON: Fulvestrant as First-Line Therapy

19. Approaches With Everolimus

20. Comments on the Main AEs

21. ESR1 Mutation

22. ESR1 Mutation: Analysis of 2 Phase 3 Trials

23. Real World Practice: Front-Line Therapy

24. Real World Practice: Disease Progression

25. NCCN Guidelines for HR-Positive Disease

26. The Future of CDK4/6 Inhibitors

27. Abbreviations